# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Geronimo (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI016-SYN
- Date: 2026-07-22
- Fictional facility: St. Posthumous Health Center
- Fictional author: Roberta Whitehorse-Lindgren, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Two-week review of sleep, nightmares and drinking, seen the same day by psychiatry. **S**

## History of present illness

Geronimo returns two weeks after intake, with the interpreter, and is seen the same day by Dr. Achebe-Varga, the visiting psychiatrist, who completed the CAPS-5 interview with him this morning. He still sleeps three or four hours a night, with nightmares most nights, and wakes ready to fight. He has cut his drinking from five or six drinks to three or four most evenings, and takes thiamine. His intake tests showed a PEth of 236 ng/mL, AST 58 and GGT 112 U/L with normal kidney function, albumin and bilirubin. A urine test today shows no opioids. He has not fallen again. He would like to try the talking treatment first and is not ready for a medicine for his mood; he will take a medicine for the drinking. **S**

| Element | Detail |
|---|---|
| Sleep | Three or four hours; nightmares most nights |
| Drinking | Three or four drinks most evenings, down from five or six |
| PCL-5 | 54 |
| CAPS-5 | Criteria met in all four symptom clusters; severity 44 |
| Urine drug test | No opioids |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Psychiatric | Positive | Nightmares, unwanted memories, startle and poor sleep; no thoughts of suicide |
| Neurological | Negative | No tremor, sweats or confusion when he drinks less |
| Gastrointestinal | Negative | No abdominal pain, jaundice or black stools |
| Musculoskeletal | Negative | Left hip bruise healing; no pain on walking |

4 systems reviewed. **S**

## Current medications

- Thiamine 100 mg oral tablet, one tablet daily **S**
- Naltrexone 50 mg oral tablet, one tablet daily; carries a wallet card saying that naltrexone blocks opioid pain medicines **S**

## Allergies

- No known allergy **S**

## Objective

BP 134/78 mmHg; pulse 78 bpm; respirations 16/min; temperature 36.5 °C; oxygen saturation 97% on room air; weight 66.2 kg; BMI 22.1 kg/m². All vital signs are synthetic.

PCL-5: 54. All results are synthetic.

## Change since baseline

- PCL-5: 56 at baseline, 54 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 134/78, pulse 78; weight 66.2 kg |
| Mental status | Alert and composed; mood tired; affect restricted; no psychotic symptoms; no thoughts of suicide or of harming anyone |
| Neurological | No tremor; steady gait |
| Abdomen | Liver edge not enlarged; no tenderness |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Post-traumatic stress disorder, chronic** (F43.12). Dr. Achebe-Varga confirms chronic post-traumatic stress disorder with the CAPS-5. Prolonged grief disorder was considered and its criteria are not met: his grief for his family is lasting but is not the daily, consuming yearning the diagnosis requires, and his mourning follows the ways of his people. Trauma-focused psychotherapy is the first treatment; he chose cognitive processing therapy. Safety reviewed: no thoughts of suicide or self-harm. **S**
   - Cognitive processing therapy, twelve weekly sessions with the interpreter, starting next week.
   - PCL-5 at each visit.
   - No medicine for PTSD for now, at his choice; no benzodiazepines.
2. **Alcohol use disorder, moderate** (F10.20). Four DSM-5-TR criteria confirmed. AST under three times the upper limit and no opioids, so naltrexone can start. Acamprosate is the alternative if he cannot take naltrexone. **S**
   - Naltrexone 50 mg daily, with a wallet card about opioid pain medicines.
   - Liver tests in four to six weeks.
   - Continue thiamine.
3. **Poor sleep with nightmares and intrusive memories** (G47.00). Explained by post-traumatic stress disorder; resolved into that diagnosis. **S**
   - Followed under post-traumatic stress disorder.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | PTSD symptom severity (PCL-5) | Baseline, then every visit during treatment | Completed today | 54, from 56 at intake |
| Survey | Structured clinician-administered interview (CAPS-5) to confirm the diagnosis | Once at diagnosis; again only if the diagnosis is in doubt | Completed today | Criteria met in all four clusters (intrusion, avoidance, negative mood and thinking, arousal); severity score 44, recorded as narrative |
| Self-management | Trauma-focused psychotherapy (cognitive processing therapy), sessions attended | Weekly for twelve sessions | Ordered | Cognitive processing therapy booked weekly from next week, with the interpreter |
| Survey | Depressive symptoms (PHQ-9) | Baseline, then monthly during active treatment | Up to date | PHQ-9 11 at intake, item 9 scored 0; next at six weeks |
| Survey | Suicide-risk review, safety plan and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; no firearm; 988 card carried |
| Self-management | Drinking since the last visit, against his own goal | Every visit | Completed today | Three or four drinks most evenings, down from five or six |
| Laboratory | Liver tests (AST, ALT, GGT) on naltrexone | Before starting, at four to six weeks, then every three to six months | Completed today | Before naltrexone: AST 58, ALT 36, GGT 112 U/L at intake; AST under three times the upper limit; creatinine 1.0 mg/dL, eGFR 78 |
| Laboratory | PEth, a blood marker of drinking over the past two to four weeks | At baseline and every one to three months during treatment, with consent | Up to date | 236 ng/mL at intake; next at about eleven weeks |
| Medication safety | Naltrexone safety: opioid use, nausea, wallet card | At the start and every visit | Completed today | Urine test negative for opioids; wallet card given |
| Medication safety | SSRI safety: sodium, bleeding, falls and side effects | Sodium within the first month in older adults; review at each dose change | Not indicated | No SSRI; he chose therapy first |
| Examination | Falls and gait (Timed Up and Go), orthostatic blood pressure | At intake and every visit after a fall | Up to date | Timed Up and Go 13 seconds at intake; no fall since |
| Self-management | Traditional healing alongside clinic care, at his choice | Every visit | Completed today | Offered again; his choice; nothing asked |
| Referral | Psychiatry consultation | At diagnosis | Completed today | Seen by Dr. Achebe-Varga today |

## Goal progress

- Sleep most nights with nightmares no more than once a week. In progress; target 2026-10-28. **S**
- Lower PTSD symptoms by a meaningful amount (PCL-5 down at least 10 to 20 points). In progress; target 2026-10-28. **S**
- Drink no more than one drink on any day, and no drinking before riding. In progress; target 2026-10-28. **S**
- No further falls. In progress; target 2026-10-28. **S**

## Medication changes

- Started: Naltrexone 50 mg oral tablet, one tablet daily; carries a wallet card saying that naltrexone blocks opioid pain medicines **S**

## Guideline basis

- VA/DoD Clinical Practice Guideline for Management of Posttraumatic Stress Disorder and Acute Stress Disorder (2023), United States Department of Veterans Affairs and Department of Defense (synopsis: Ann Intern Med 2024;177(3):363-374)
- Clinical Practice Guideline for the Treatment of Posttraumatic Stress Disorder (PTSD) in Adults (2017), American Psychological Association
- The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder (2018), American Psychiatric Association (Am J Psychiatry 2018;175(1):86-90)
- The Healthcare Professional's Core Resource on Alcohol (2026), National Institute on Alcohol Abuse and Alcoholism
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- Special General Memorandum 94-08: Statement of Policy for the Traditional Cultural Advocacy Program (1994), Indian Health Service

## Follow-up

- Six-week review with liver tests. Cognitive processing therapy weekly from next week. Call the clinic or 988 at any hour. **S**
- Next scheduled visit 2026-08-19: six-week review: cognitive processing therapy, naltrexone, sleep, mood and medicine. **S**
